Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
Palvella Therapeutics (PVLA), a clinical-stage biopharmaceutical company focused on developing therapies for rare genetic skin diseases, announced it will ring the Nasdaq opening bell on May 12, 2025. The ceremony, led by CEO Wes Kaupinen along with management team, board members, investors, and advisors, will begin at 9:15 am ET at the Nasdaq MarketSite Tower in New York City.
The event marks Palvella's milestone as a publicly traded, Nasdaq-listed company. The company specializes in developing treatments for serious, rare genetic skin diseases that currently lack FDA-approved therapies. The ceremony will be live-streamed on Nasdaq's X and Facebook pages.
Palvella Therapeutics (PVLA), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per malattie genetiche rare della pelle, ha annunciato che suonerà la campana di apertura del Nasdaq il 12 maggio 2025. La cerimonia, guidata dall'amministratore delegato Wes Kaupinen insieme al team di gestione, ai membri del consiglio, agli investitori e ai consulenti, inizierà alle 9:15 am ET presso il Nasdaq MarketSite Tower di New York City.
L'evento rappresenta un traguardo importante per Palvella, ora società quotata pubblicamente al Nasdaq. L'azienda si concentra nello sviluppo di trattamenti per gravi malattie genetiche rare della pelle, per le quali attualmente non esistono terapie approvate dalla FDA. La cerimonia sarà trasmessa in diretta sulle pagine X e Facebook di Nasdaq.
Palvella Therapeutics (PVLA), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar terapias para enfermedades genéticas raras de la piel, anunció que tocará la campana de apertura del Nasdaq el 12 de mayo de 2025. La ceremonia, liderada por el CEO Wes Kaupinen junto con el equipo directivo, miembros del consejo, inversores y asesores, comenzará a las 9:15 am ET en la Torre Nasdaq MarketSite en la ciudad de Nueva York.
El evento marca un hito para Palvella como compañía pública cotizada en Nasdaq. La empresa se especializa en desarrollar tratamientos para enfermedades genéticas raras y graves de la piel que actualmente no cuentan con terapias aprobadas por la FDA. La ceremonia será transmitida en vivo en las páginas de Nasdaq en X y Facebook.
Palvella Therapeutics (PVLA)는 희귀 유전성 피부 질환 치료제 개발에 주력하는 임상 단계 바이오제약 회사로, 2025년 5월 12일 나스닥 개장 종을 울릴 예정이라고 발표했습니다. CEO Wes Kaupinen과 경영진, 이사회 구성원, 투자자 및 자문단이 함께하는 이 행사는 동부 표준시 오전 9시 15분에 뉴욕시 나스닥 마켓사이트 타워에서 시작됩니다.
이번 행사는 Palvella가 나스닥에 상장된 공개 기업으로서의 중요한 이정표를 의미합니다. 회사는 현재 FDA 승인 치료제가 없는 심각하고 희귀한 유전성 피부 질환 치료제 개발에 주력하고 있습니다. 이 행사는 나스닥의 X 및 페이스북 페이지에서 생중계될 예정입니다.
Palvella Therapeutics (PVLA), une société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies pour les maladies génétiques rares de la peau, a annoncé qu'elle sonnera la cloche d'ouverture du Nasdaq le 12 mai 2025. La cérémonie, dirigée par le PDG Wes Kaupinen avec l'équipe de direction, les membres du conseil d'administration, les investisseurs et les conseillers, débutera à 9h15 ET à la tour Nasdaq MarketSite à New York.
L'événement marque une étape importante pour Palvella en tant que société cotée en bourse au Nasdaq. L'entreprise se spécialise dans le développement de traitements pour des maladies génétiques rares et graves de la peau, pour lesquelles il n'existe actuellement aucun traitement approuvé par la FDA. La cérémonie sera diffusée en direct sur les pages X et Facebook de Nasdaq.
Palvella Therapeutics (PVLA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für seltene genetische Hautkrankheiten spezialisiert hat, gab bekannt, dass es am 12. Mai 2025 die Nasdaq-Eröffnungsglocke läuten wird. Die Zeremonie, geleitet vom CEO Wes Kaupinen zusammen mit dem Management-Team, Vorstandsmitgliedern, Investoren und Beratern, beginnt um 9:15 Uhr ET im Nasdaq MarketSite Tower in New York City.
Die Veranstaltung markiert einen Meilenstein für Palvella als börsennotiertes Unternehmen an der Nasdaq. Das Unternehmen spezialisiert sich auf die Entwicklung von Behandlungen für schwere, seltene genetische Hautkrankheiten, für die derzeit keine von der FDA zugelassenen Therapien existieren. Die Zeremonie wird live auf den X- und Facebook-Seiten von Nasdaq übertragen.
- None.
- None.
WAYNE, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that the Company will ring the opening bell at the Nasdaq Stock Market (Nasdaq) on Monday, May 12, 2025 in New York City.
Wes Kaupinen, Founder and Chief Executive Officer, will be joined by members of the Palvella management team, Board of Directors, investors, advisors, and guests at the ceremony which will begin at approximately 9:15 am ET.
“We are honored to have been invited by Nasdaq to participate in the opening bell ceremony and highlight Palvella’s vision to build the leading rare disease biopharmaceutical company serving individuals afflicted with serious, rare genetic skin diseases,” said Mr. Kaupinen. “Becoming a publicly traded, Nasdaq-listed company is a major corporate milestone which was made possible through the unwavering support of our investors, physician and scientific collaborators, patient advocacy partners, and our dedicated management team and advisors.”
The live broadcast will begin at 9:15 am ET and will be live-streamed from the Nasdaq MarketSite Tower in New York City and available on Nasdaq’s X and Facebook pages.
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN
QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from ongoing clinical trials, Palvella’s clinical development plans and related anticipated development milestones, Palvella’s cash and financial resources and expected cash runway, and the potential of, and expectations regarding, Palvella’s programs, including QTORIN™ rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN™ rapamycin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com
FAQ
When will Palvella Therapeutics (PVLA) ring the Nasdaq opening bell?
What is Palvella Therapeutics' (PVLA) main business focus?
Who will participate in PVLA's Nasdaq bell ringing ceremony?
Where can I watch Palvella Therapeutics' Nasdaq bell ringing ceremony?
